GROWTH FACTORS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to advancing the field of cell biology, clinical biochemistry, and endocrinology. With an ISSN of 0897-7194 and an E-ISSN of 1029-2292, this journal has served as a vital platform for the dissemination of groundbreaking research since its inception in 1988. Although it operates without an Open Access model, GROWTH FACTORS focuses on providing high-quality, peer-reviewed articles that explore the intricate roles of growth factors in biological processes and their implications in health and disease. Holding a Q4 ranking in Cell Biology and Q3 rankings in Clinical Biochemistry and Endocrinology according to the 2023 category quartiles, the journal is well-regarded in its field and plays a crucial role in informing researchers, professionals, and students alike about the latest findings and innovations in these areas. The journal's commitment to fostering scientific dialogue ensures that it remains a key resource for those looking to enhance their understanding of growth factors and their applications in clinical settings.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

MOLECULAR BIOLOGY, published by PLEIADES PUBLISHING INC, serves as a vital repository for the dissemination of innovative research within the fields of biochemistry, genetics, and molecular biology. With an ISSN of 0026-8933 and an E-ISSN of 1608-3245, this journal has been a mainstay in the scientific community since its inception, embracing its deep historical roots from 1971 to the present. Recognized for its qualitative contributions, MOLECULAR BIOLOGY is ranked in the Q3 quartile for Biophysics and Q4 for Structural Biology, placing it among select journals in its domain. Researchers and students alike benefit from its rigorous peer-reviewed articles, which focus on all aspects of molecular mechanisms and interactions. The journal's inclusion in prestigious databases underlines its commitment to academic excellence. The editorial board is dedicated to fostering the sharing of influential findings, making it an essential resource for advancing knowledge and innovation in molecular biology.

JOURNAL OF PROTEOME RESEARCH is a premier publication in the field of proteomics, disseminating cutting-edge research and methodologies that drive advancements in biochemistry and molecular biology. Published by the American Chemical Society, this esteemed journal boasts a robust impact, as evidenced by its Q1 rankings in both Biochemistry and miscellaneous Chemistry categories for 2023. With a reputation bolstered by a solid Scopus ranking—#64 out of 408 in General Chemistry and #80 out of 438 in Biochemistry—the journal serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of protein functions and interactions in biological systems. Although it does not operate under an open-access model, the JOURNAL OF PROTEOME RESEARCH remains a critical platform for scholarly discourse, committed to publishing high-quality, peer-reviewed articles through 2024 and beyond. Scholars are encouraged to engage with the pioneering studies and reviews that shape the future of proteomics.

Comparative Biochemistry and Physiology D-Genomics & Proteomics, published by Elsevier Science Inc, is a premier journal in the realm of molecular biology and comparative physiology, with a focus on genomic and proteomic sciences. Recognized for its high-impact contributions, it holds a Q1 ranking in Animal Science and Zoology and was established with the vision of bridging gaps in our understanding of biological systems through experimental and comparative approaches. With an impressive Scopus ranking, this journal not only ranks among the top 12% in Animal Science and Zoology but also demonstrates commendable standings across various categories including Aquatic Science and Molecular Biology. The journal’s commitment to disseminating high-quality research makes it an essential resource for researchers, professionals, and students alike, allowing them to access critical studies that influence advancements in genomics and proteomics. While it operates under a traditional subscription model, its impactful findings are crucial for those aiming to enrich their knowledge and research capabilities in these pivotal scientific fields. Join us in exploring the transformative insights and developments that this esteemed journal has to offer for the study of genomics and proteomics.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, published by Elsevier, is a prestigious academic journal that serves as a vital resource for researchers, professionals, and students in the fields of biochemistry, biophysics, and proteomics. With an ISSN of 1570-9639 and an E-ISSN of 1878-1454, this journal features high-impact research articles aimed at advancing our understanding of protein structure, function, and interactions, contributing significantly to both theoretical and applied sciences. Recognized for its quality, it proudly holds a Q1 ranking in Analytical Chemistry and Biophysics, and Q2 in Biochemistry for 2023, alongside notable Scopus rankings that reflect its influence in the realm of molecular biology. The journal's commitment to disseminating essential findings supports the ongoing evolution of proteomic sciences and encourages collaborative discourse among the global scientific community. For aspiring authors, the journal offers open access options, enabling broad visibility of their work. Join the conversation in this dynamic field and contribute to shaping the future of protein research!

Proteomics Clinical Applications, published by Wiley-VCH Verlag GmbH, is a pivotal journal in the realm of Clinical Biochemistry, with an impressive track record since its inception in 2007, continuing its impactful contributions to 2024. With an ISSN of 1862-8346 and an E-ISSN of 1862-8354, this prestigious journal currently holds a commendable Q2 ranking in Clinical Biochemistry, situated at the 54th percentile among its peers within Scopus rankings. Dedicated to the advancement of proteomics and its applications in clinical settings, Proteomics Clinical Applications serves as a bastion for innovative research, fostering knowledge exchange among scientists, healthcare professionals, and students alike. Through its focus on novel methodologies and translational research, the journal aims to bridge the gap between laboratory findings and clinical practice, significantly impacting patient care and outcomes. Although not open access, its content is accessible through various academic databases, ensuring that vital research reaches its intended audience.

PROTEOMICS is a leading journal focused on the rapidly evolving field of proteomics, published by WILEY in Germany. With a solid reputation established since its inception in 2001, it has continually contributed to the understanding of protein functions and interactions within biological systems. As part of its commitment to academic excellence, PROTEOMICS is ranked in the second quartile for both Biochemistry and Molecular Biology categories (2023), reflecting its significant influence in advancing research in these areas. Although it does not currently provide open access options, it remains a vital resource for researchers, professionals, and students keen to explore innovative methodologies and findings in proteomic research. By publishing groundbreaking studies that bridge theoretical knowledge with practical applications, PROTEOMICS plays a crucial role in enhancing our understanding of molecular processes and driving forward advancements in the life sciences.

Molecular Omics is a premier, peer-reviewed journal published by the Royal Society of Chemistry, focusing on the interdisciplinary field of molecular biology with significant implications for biochemistry and genetics. With an E-ISSN of 2515-4184, this journal has been dedicated to disseminating high-quality research since its inception in 2018, maintaining an impressive trajectory in academic contributions until 2024. Currently, it holds a Q2 quartile ranking in both Biochemistry and Genetics, alongside a Q3 ranking in Molecular Biology for 2023, highlighting its relevance and influence in these domains. The journal is accessible as an open access publication, promoting the widespread dissemination of groundbreaking research. As part of a vibrant academic community, Molecular Omics aims to bridge fundamental and applied science, appealing to researchers, professionals, and students eager to expand their knowledge on molecular mechanisms and technologies that shape the future of biological research.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.